Logo image of SPRY

ARS PHARMACEUTICALS INC (SPRY) Stock Fundamental Analysis

NASDAQ:SPRY - Nasdaq - US82835W1080 - Common Stock - Currency: USD

13.935  -0.7 (-4.82%)

Fundamental Rating

5

SPRY gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. SPRY is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. While showing a medium growth rate, SPRY is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

SPRY had positive earnings in the past year.
In the past year SPRY had a positive cash flow from operations.
SPRY had negative earnings in 4 of the past 5 years.
SPRY had negative operating cash flow in 4 of the past 5 years.
SPRY Yearly Net Income VS EBIT VS OCF VS FCFSPRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

SPRY has a Return On Assets of 2.28%. This is amongst the best in the industry. SPRY outperforms 92.25% of its industry peers.
The Return On Equity of SPRY (3.11%) is better than 93.13% of its industry peers.
Industry RankSector Rank
ROA 2.28%
ROE 3.11%
ROIC N/A
ROA(3y)-11.12%
ROA(5y)-13.71%
ROE(3y)-11.05%
ROE(5y)-14.05%
ROIC(3y)N/A
ROIC(5y)N/A
SPRY Yearly ROA, ROE, ROICSPRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

Looking at the Profit Margin, with a value of 8.97%, SPRY belongs to the top of the industry, outperforming 93.31% of the companies in the same industry.
SPRY's Gross Margin of 99.02% is amongst the best of the industry. SPRY outperforms 97.71% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 8.97%
GM 99.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRY Yearly Profit, Operating, Gross MarginsSPRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K

More info and screens

8

2. Health

2.1 Basic Checks

SPRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPRY has been increased compared to 1 year ago.
The number of shares outstanding for SPRY has been increased compared to 5 years ago.
SPRY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SPRY Yearly Shares OutstandingSPRY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SPRY Yearly Total Debt VS Total AssetsSPRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

SPRY has an Altman-Z score of 9.93. This indicates that SPRY is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 9.93, SPRY belongs to the best of the industry, outperforming 88.03% of the companies in the same industry.
There is no outstanding debt for SPRY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 9.93
ROIC/WACCN/A
WACC10.3%
SPRY Yearly LT Debt VS Equity VS FCFSPRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

SPRY has a Current Ratio of 14.26. This indicates that SPRY is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SPRY (14.26) is better than 88.91% of its industry peers.
A Quick Ratio of 14.04 indicates that SPRY has no problem at all paying its short term obligations.
SPRY has a better Quick ratio (14.04) than 88.38% of its industry peers.
Industry RankSector Rank
Current Ratio 14.26
Quick Ratio 14.04
SPRY Yearly Current Assets VS Current LiabilitesSPRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

SPRY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 108.77%, which is quite impressive.
SPRY shows a strong growth in Revenue. In the last year, the Revenue has grown by 297063.33%.
EPS 1Y (TTM)108.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%800%
Revenue 1Y (TTM)297063.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 88.12% on average over the next years. This is a very strong growth
SPRY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 104.65% yearly.
EPS Next Y-2867.61%
EPS Next 2Y-267.31%
EPS Next 3Y69.33%
EPS Next 5Y88.12%
Revenue Next Year380.02%
Revenue Next 2Y240.61%
Revenue Next 3Y163.51%
Revenue Next 5Y104.65%

3.3 Evolution

SPRY Yearly Revenue VS EstimatesSPRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SPRY Yearly EPS VS EstimatesSPRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 278.70, which means the current valuation is very expensive for SPRY.
Compared to the rest of the industry, the Price/Earnings ratio of SPRY indicates a rather cheap valuation: SPRY is cheaper than 91.73% of the companies listed in the same industry.
SPRY is valuated expensively when we compare the Price/Earnings ratio to 28.92, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for SPRY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 278.7
Fwd PE N/A
SPRY Price Earnings VS Forward Price EarningsSPRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200 250

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of SPRY indicates a rather cheap valuation: SPRY is cheaper than 93.13% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 105.3
EV/EBITDA N/A
SPRY Per share dataSPRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as SPRY's earnings are expected to grow with 69.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-267.31%
EPS Next 3Y69.33%

More info and screens

0

5. Dividend

5.1 Amount

SPRY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARS PHARMACEUTICALS INC

NASDAQ:SPRY (4/25/2025, 2:27:28 PM)

13.935

-0.7 (-4.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-20 2025-03-20/bmo
Earnings (Next)05-09 2025-05-09/bmo
Inst Owners66.89%
Inst Owner ChangeN/A
Ins Owners18.28%
Ins Owner Change-0.76%
Market Cap1.37B
Analysts88.33
Price Target32.23 (131.29%)
Short Float %28.93%
Short Ratio10.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)205.1%
Min EPS beat(2)-32.93%
Max EPS beat(2)443.14%
EPS beat(4)2
Avg EPS beat(4)100.73%
Min EPS beat(4)-32.93%
Max EPS beat(4)443.14%
EPS beat(8)5
Avg EPS beat(8)59.11%
EPS beat(12)6
Avg EPS beat(12)89.66%
EPS beat(16)8
Avg EPS beat(16)63.12%
Revenue beat(2)2
Avg Revenue beat(2)344.62%
Min Revenue beat(2)252.6%
Max Revenue beat(2)436.64%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.77%
PT rev (3m)8.97%
EPS NQ rev (1m)-94.76%
EPS NQ rev (3m)-46.48%
EPS NY rev (1m)-284.87%
EPS NY rev (3m)-271.69%
Revenue NQ rev (1m)-46.57%
Revenue NQ rev (3m)-27.9%
Revenue NY rev (1m)-28.27%
Revenue NY rev (3m)-25.87%
Valuation
Industry RankSector Rank
PE 278.7
Fwd PE N/A
P/S 15.34
P/FCF 105.3
P/OCF 100.92
P/B 5.32
P/tB 5.48
EV/EBITDA N/A
EPS(TTM)0.05
EY0.36%
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)0.13
FCFY0.95%
OCF(TTM)0.14
OCFY0.99%
SpS0.91
BVpS2.62
TBVpS2.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.28%
ROE 3.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 8.97%
GM 99.02%
FCFM 14.57%
ROA(3y)-11.12%
ROA(5y)-13.71%
ROE(3y)-11.05%
ROE(5y)-14.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 712.66%
Cap/Sales 0.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 162.35%
Current Ratio 14.26
Quick Ratio 14.04
Altman-Z 9.93
F-Score7
WACC10.3%
ROIC/WACCN/A
Cap/Depr(3y)338.3%
Cap/Depr(5y)266.86%
Cap/Sales(3y)199.71%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)108.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%800%
EPS Next Y-2867.61%
EPS Next 2Y-267.31%
EPS Next 3Y69.33%
EPS Next 5Y88.12%
Revenue 1Y (TTM)297063.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year380.02%
Revenue Next 2Y240.61%
Revenue Next 3Y163.51%
Revenue Next 5Y104.65%
EBIT growth 1Y95.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-119.75%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y121.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y122.86%
OCF growth 3YN/A
OCF growth 5YN/A